A mucoactive aromatic amine.
Potential treatment - pre-clinical evidence
Ambroxol is used in the treatment of respiratory diseases associated with viscid or excessive mucus. It has secretolytic properties (DrugBank). The compound was shown to prevent the activation of acid sphingomyelinase and the release of ceramide, which was proposed to be a crucial step during the SARS-CoV-2 infection (Carpinteiro et al., 2021).
MUCOSOLVAN; AMBROBENE; AMBROXOL; SOLVOLAN
|Link||Tested on||Impact factor||Notes||Publication date|
Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies
In silico TMPRSS2 inhibitors screening.
Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells
Small molecule Enzyme assay In vitro Mechanism
|in vitro enzyme assay; Vero E6 cells; Caco-2 cells nasal epithelial cells ; (VSV) SARS-CoV-2 Spike-pseudotyped virus||4.24||
Ambroxol prevented the activation of acid sphingomyelinase and the release of ceramide, which led to inhibition of cell entry by SARS-CoV-2 pseudovirus.